AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33670796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette use
Number of subjects: 322
Study 33670796 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 322
Study 33670796 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 322
Study 33670796 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 322
Study 33670796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 322
Study 33671555 — intervention group
Group type: EXPERIMENTAL
Intervention: IO103 vaccine with Montanide adjuvant
Number of subjects: 10
Study 33671691 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic product (1 capsule/day)
Number of subjects: 0
Study 33671691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33673615 — intervention group
Group type: EXPERIMENTAL
Intervention: V-V ECMO
Number of subjects: 127
Study 33673868 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable patch for remote monitoring of vital signs (heart rate, respiratory rate, temperature) during stay in hotel quarantine.
Number of subjects: 0
Study 33673868 — intervention group
Group type: EXPERIMENTAL
Intervention: Central monitoring hub for nursing staff to view notifications of deterioration.
Number of subjects: 0
Study 33673873 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted pterygium surgery (FLAPS) with conjunctival autograft (CAG)
Number of subjects: 29
Study 33673873 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted pterygium surgery (FLAPS) with ultrathin CAG (mean thickness of 74.5 ± 9.8 μm)
Number of subjects: 29
Study 33673929 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenzilumab
Number of subjects: 0
Study 33673929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33674274 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (10 mg/day, days 1-5) plus camrelizumab (200 mg, day 8), every 3 weeks
Number of subjects: 51
Study 33674354 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 0
Study 33674354 — intervention group
Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 0
Study 33674398 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin-releasing peptide receptor-targeting PET
Number of subjects: 50
Study 33674398 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-targeted PET
Number of subjects: 50
Study 33674398 — intervention group
Group type: COMPARATOR
Intervention: Standard imaging techniques
Number of subjects: 50
Study 33674419 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rheumatoid arthritis (ERA) group
Number of subjects: 56
Study 33674419 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 56
Study 33674856 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook group intervention to reduce barriers to evidence-based smoking cessation treatment
Number of subjects: 70
Study 33675034 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 0
Study 33675179 — intervention group
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin 2.4 mg/kg
Number of subjects: 9
Study 33675179 — intervention group
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin 2.7 mg/kg
Number of subjects: 9
Study 33675179 — intervention group
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (both doses)
Number of subjects: 9
Study 33675184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with TI-CE regimen, including two cycles of paclitaxel and ifosfamide followed by three cycles of HD carboplatin plus etoposide, with carboplatin dose adapted based on clearance to reach a target AUC of 24 mg.min/mL per cycle.
Number of subjects: 89
Study 33675184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with TI-CE regimen.
Number of subjects: 89
Study 33675184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with TI-CE regimen for high- and very high-risk patients.
Number of subjects: 89
Study 33675321 — intervention group
Group type: EXPERIMENTAL
Intervention: Irish calculator (IC)
Number of subjects: 0
Study 33675321 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified definition of DGF (excluding those with single dialysis in the first 24 h posttransplant)
Number of subjects: 0
Study 33675321 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient cardiovascular disease
Number of subjects: 0
Study 33675592 — intervention group
Group type: EXPERIMENTAL
Intervention: Aktiia Bracelet
Number of subjects: 86
Study 33675635 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased physical activity (reported by 53% of participants)
Number of subjects: 37252
Study 33675635 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sedentary time (reported by 63%)
Number of subjects: 37252
Study 33675635 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased snacking
Number of subjects: 37252
Study 33675635 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased consumption of fresh food (especially fruit and fish)
Number of subjects: 37252
Study 33675635 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of sweets, cookies, and cakes
Number of subjects: 37252
Study 33675635 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased home cooking (reported by 40%)
Number of subjects: 37252
Study 33675635 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity (reported by 19%)
Number of subjects: 37252
Study 33675635 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (35% of participants, mean weight gain 1.8 kg ± SD 1.3 kg)
Number of subjects: 37252
Study 33675635 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (23% of participants, mean weight loss 2 kg ± SD 1.4 kg)
Number of subjects: 37252
Study 33675642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative high-frequency ultrasound and transit-time flow measurement (TTFM) in CABG procedures
Number of subjects: 1016
Study 33675642 — intervention group
Group type: COMPARATOR
Intervention: Normal renal function
Number of subjects: 1016
Study 33675642 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-protamine graft TTFM parameters
Number of subjects: 1016
Study 33676017 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 38
Study 33676165 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with Ph-negative ALL
Number of subjects: 15
Study 33676165 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women with Ph-negative ALL
Number of subjects: 15
Study 33676426 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 155
Study 33676431 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm Phase (AP)
Number of subjects: 162
Study 33676431 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Phase (UCP)
Number of subjects: 162
Study 33676455 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (preferred genre, wireless headphones for up to 30 minutes)
Number of subjects: 172
Study 33676547 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 61
Study 33676628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib 200 mg daily
Number of subjects: 323
Study 33677480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) alone
Number of subjects: 40
Study 33677480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (anti-PD-1 and anti-CTLA-4) combination therapy
Number of subjects: 40
Study 33677504 — intervention group
Group type: COMPARATOR
Intervention: Congenital adrenal hyperplasia (CAH) patients
Number of subjects: 57
Study 33677504 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased mineralocorticoid dose during childhood
Number of subjects: 57
Study 33677504 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressed androstenedione during adulthood
Number of subjects: 57
Study 33677504 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressed testosterone during adulthood
Number of subjects: 57
Study 33677504 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated 17-hydroxyprogesterone in children
Number of subjects: 57
Study 33677504 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 57
Study 33677530 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33677532 — intervention group
Group type: EXPERIMENTAL
Intervention: AFB1-lysine adduct concentrations
Number of subjects: 1675
Study 33677532 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum aflatoxin concentrations
Number of subjects: 1675
Study 33677553 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical renal denervation (RDN) using Peregrine System Infusion Catheter, Ablative Solutions (n = 4; 2F:2M)
Number of subjects: 7
Study 33677553 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical renal denervation (RDN)
Number of subjects: 7
Study 33677553 — intervention group
Group type: COMPARATOR
Intervention: Control renal angiography (n = 3; 2F:1M)
Number of subjects: 7
Study 33677615 — intervention group
Group type: EXPERIMENTAL
Intervention: UGN-101 (mitomycin-containing reverse thermal gel)
Number of subjects: 6
Study 33677695 — intervention group
Group type: COMPARATOR
Intervention: Sedation
Number of subjects: 79
Study 33677695 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sedation
Number of subjects: 79
Study 33677832 — intervention group
Group type: COMPARATOR
Intervention: DBT-A
Number of subjects: 2280
Study 33677832 — intervention group
Group type: COMPARATOR
Intervention: Individual CBT-based psychotherapy
Number of subjects: 2280
Study 33677832 — intervention group
Group type: COMPARATOR
Intervention: Mentalisation based therapy for adolescents (MBT-A)
Number of subjects: 2280
Study 33677832 — intervention group
Group type: COMPARATOR
Intervention: Family therapy
Number of subjects: 2280
Study 33677832 — intervention group
Group type: COMPARATOR
Intervention: Compliance enhancement approaches
Number of subjects: 2280
Study 33677832 — intervention group
Group type: COMPARATOR
Intervention: Group-based psychotherapy
Number of subjects: 2280
Study 33677832 — intervention group
Group type: COMPARATOR
Intervention: Remote contact intervention (emergency cards)
Number of subjects: 2280
Study 33677832 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic assessment
Number of subjects: 2280
Study 33677986 — intervention group
Group type: EXPERIMENTAL
Intervention: ART experienced individuals
Number of subjects: 44
Study 33677986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir treatment
Number of subjects: 44
Study 33677986 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC treatment
Number of subjects: 44
Study 33678938 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients
Number of subjects: 6217
Study 33679057 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% end-tidal sevoflurane
Number of subjects: 21
Study 33679057 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% end-tidal sevoflurane
Number of subjects: 21
Study 33679057 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative RVOT gradient
Number of subjects: 21
Study 33679255 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous Breathing (SB)
Number of subjects: 0
Study 33679255 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 0
Study 33679255 — intervention group
Group type: COMPARATOR
Intervention: Controlled Ventilation
Number of subjects: 0
Study 33679374 — intervention group
Group type: EXPERIMENTAL
Intervention: Management modalities for brain AVMs
Number of subjects: 0
Study 33679374 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33679432 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker-light induced retinal vessel dilatation (FID)
Number of subjects: 18
Study 33679432 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-induced myogenic constriction
Number of subjects: 18
Study 33679447 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-load PRT
Number of subjects: 30
Study 33679447 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load PRT
Number of subjects: 30
Study 33679447 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise
Number of subjects: 30
Study 33679469 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostatic sleep pressure buildup, specific details not available
Number of subjects: 0
Study 33679478 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-Administered Emotional Awareness and Expression Therapy
Number of subjects: 0
Study 33679478 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33679529 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based active lifestyle intervention including teacher training, environmental improvements, and educational strategies.
Number of subjects: 0
Study 33679529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 0
Study 33679572 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 10 Hz rTMS stimulation with the H2-coil
Number of subjects: 30
Study 33679572 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS stimulation
Number of subjects: 30
Study 33680117 — intervention group
Group type: EXPERIMENTAL
Intervention: Danon disease patients (n=7)
Number of subjects: 7
Study 33680364 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33681244 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved use of chewing gum during capsule endoscopy
Number of subjects: 0
Study 33681244 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard procedure without chewing gum)
Number of subjects: 0
Study 33681273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Approach
Number of subjects: 0
Study 33681273 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatments (three different types)
Number of subjects: 0
Study 33681273 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33681680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC)
Number of subjects: 24
Study 33681685 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Number of subjects: 1841
Study 33681744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (5 mg)
Number of subjects: 206
Study 33681744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 206
Study 33681744 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 206
Study 33681747 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg nightly for one year)
Number of subjects: 709
Study 33681747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nightly for one year)
Number of subjects: 709
Study 33681776 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) - 3 cycles, BP cuff inflated to 30 mm Hg above systolic BP
Number of subjects: 75
Study 33681776 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention - BP cuff inflated to 30 mm Hg below diastolic BP
Number of subjects: 75
Study 33682355 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-HPV (DH3)
Number of subjects: 5171
Study 33682355 — intervention group
Group type: COMPARATOR
Intervention: Cytology test
Number of subjects: 5171
Study 33682355 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 viral load
Number of subjects: 5171
Study 33682355 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 and other 12 HR-HPV
Number of subjects: 5171
Study 33682430 — intervention group
Group type: EXPERIMENTAL
Intervention: Somryst™ (digital therapeutic for insomnia)
Number of subjects: 350
Study 33682447 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin combined with novel agents (GSK3174998, feladilimab, nirogacestat, dostarlimab)
Number of subjects: 0
Study 33682447 — intervention group
Group type: COMPARATOR
Intervention: Belantamab mafodotin monotherapy
Number of subjects: 0
Study 33682527 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid receptor antagonists, specific dosage and duration not mentioned
Number of subjects: 0
Study 33682527 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33682678 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously once daily for 10 days
Number of subjects: 130
Study 33682678 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care comparators
Number of subjects: 130
Study 33682716 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive baseline amyloid PET
Number of subjects: 25
Study 33682716 — intervention group
Group type: COMPARATOR
Intervention: Negative baseline amyloid PET
Number of subjects: 25
Study 33683342 — intervention group
Group type: EXPERIMENTAL
Intervention: NLRP3 inflammasome stimulation in peripheral myeloid cells from COVID-19 patients
Number of subjects: 0
Study 33683342 — intervention group
Group type: EXPERIMENTAL
Intervention: NLRP3 inflammasome stimulation in peripheral myeloid cells from recovered COVID-19 patients
Number of subjects: 0
Study 33683342 — intervention group
Group type: COMPARATOR
Intervention: Healthy donors (control group)
Number of subjects: 0
Study 33683482 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel and cisplatin
Number of subjects: 80
Study 33683482 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel monotherapy
Number of subjects: 80
Study 33683582 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram monotherapy (n = 82, ESC-CONT)
Number of subjects: 209
Study 33683582 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive Aripiprazole (n = 88, ESC-ARI)
Number of subjects: 209
Study 33683582 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (n = 112)
Number of subjects: 209
Study 33683917 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbralisib 800 mg orally once daily until disease progression, unacceptable toxicity, or study withdrawal
Number of subjects: 208
Study 33683917 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbralisib 800 mg orally once daily
Number of subjects: 208
Study 33684111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined water and sanitation intervention
Number of subjects: 471
Study 33684111 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 471
Study 33684111 — intervention group
Group type: COMPARATOR
Intervention: MPO (biomarker)
Number of subjects: 471
Study 33684111 — intervention group
Group type: COMPARATOR
Intervention: NEO (biomarker)
Number of subjects: 471
Study 33684111 — intervention group
Group type: COMPARATOR
Intervention: AAT (biomarker)
Number of subjects: 471
Study 33684160 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1070806 (3 mg/kg intravenous)
Number of subjects: 7
Study 33684371 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33684377 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG) at 0.1 g/kg/week for up to 6 months
Number of subjects: 20
Study 33684377 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 20
Study 33684474 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith t-Branch multibranched thoracoabdominal stent-graft
Number of subjects: 80
Study 33684930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrheal samples with low Megasphaera abundance
Number of subjects: 72
Study 33684930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-infection microbiome composition
Number of subjects: 72
Study 33684930 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome composition broadly
Number of subjects: 72
Study 33685522 — intervention group
Group type: EXPERIMENTAL
Intervention: MANTRa therapy (24 to 34 individual weekly sessions)
Number of subjects: 100
Study 33685522 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual, weekly sessions)
Number of subjects: 100
Study 33685522 — intervention group
Group type: EXPERIMENTAL
Intervention: MANTRa therapy
Number of subjects: 100
Study 33685522 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 100
Study 33685975 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 11
Study 33686413 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised luteal phase support (iLPS) through daily subcutaneous P4 injections (Psc) started the day prior to FET.
Number of subjects: 574
Study 33686452 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) in combination with LY3023414
Number of subjects: 63
Study 33686452 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) in combination with abemaciclib
Number of subjects: 63
Study 33686452 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478) in combination with taladegib
Number of subjects: 63
Study 33686452 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenigacestat (LY3039478)
Number of subjects: 63
Study 33686472 — intervention group
Group type: EXPERIMENTAL
Intervention: COMMANDER-HF
Number of subjects: 3
Study 33686472 — intervention group
Group type: EXPERIMENTAL
Intervention: EPHESUS
Number of subjects: 3
Study 33686472 — intervention group
Group type: EXPERIMENTAL
Intervention: EXAMINE
Number of subjects: 3
Study 33686472 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 3
Study 33686542 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional measures including maximal cardiopulmonary exercise testing (CPET)
Number of subjects: 39
Study 33686542 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans Specific Activity Questionnaire (VSAQ)
Number of subjects: 39
Study 33686542 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT)
Number of subjects: 39
Study 33686542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests
Number of subjects: 39
Study 33686542 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition determined by dual X-ray absorptiometry
Number of subjects: 39